Evidence map›Paper›PMID 37736642›Full record

ArticleChemical science2023

Concise synthesis of (

Emmanuel Cigan, Jakob Pletz, Sarah A Berger, Bettina Hierzberger, Michael Grilec-Zlamal, Alexander Steiner, Isabel Oroz-Guinea, Wolfgang Kroutil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emmanuel CiganInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.ORCID https://orcid.org/0000-0002-3916-2424
Jakob PletzInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Sarah A BergerInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Bettina HierzbergerInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Michael Grilec-ZlamalInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Alexander SteinerInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Isabel Oroz-GuineaInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.
Wolfgang KroutilInstitute of Chemistry, University of Graz, NAWI Graz, BioTechMed Graz Heinrichstrasse 28/II 8010 Graz Austria Wolfgang.Kroutil@uni-graz.at.ORCID https://orcid.org/0000-0002-2151-6394

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficient access to the morphinan scaffold remains a major challenge in both synthetic chemistry and biotechnology. Here, a biomimetic chemo-enzymatic strategy to synthesize the natural promorphinan intermediate (+)-salutaridine is demonstrated. By combining early-stage organic synthesis with enzymatic asymmetric key step transformations, the prochiral natural intermediate 1,2-dehydroreticuline was prepared and subsequently stereoselectively reduced by the enzyme 1,2-dehydroreticuline reductase obtaining (

Identifiers

PMID37736642
PMCPMC10510765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.